The Vanderbilt-Ingram Cancer Center (VICC) is a National Cancer Institute-designated Comprehensive Cancer Center in Nashville, Tennessee that conducts basic, translational and clinical research offering adult and pediatric oncology treatment. Additionally we are part of the National Comprehensive Cancer Network (NCCN), a non-profit alliance of 27 of the world's leading cancer centers. Our clinicians are privileged to serve more than 6,252 new cancer patients and deliver care for more than 151,000 outpatient visits each year. Comprised of nearly 300 researchers in eight research programs, VICC is also at the forefront of promising new therapies with access to over 150 clinical trials at any given time.
The Department of Pharmacy Specialty Oncology Residency is a 12-month program. The graduate will obtain the specialized oncology knowledge base and clinical skills required to become competent in the pharmaceutical care of cancer patients. We are an accredited residency program by ASHP and follow their guidelines and vision closely. The resident will have opportunities in all aspects of oncology pharmacy practice related to clinical practice and outcomes, short-term research projects, and educating other health care professionals. All rotations are four weeks in duration. The resident schedule is flexible in order to allow the resident to meet his/her career goals and interests.
Required Longitudinal Experiences:
|Benefits||Current Oncology Resident|
|TN Board of Pharmacy & NABP||Vanderbilt Community|
Applicant must be a graduate of an accredited Doctor of Pharmacy program, be a licensed pharmacist in any state with reciprocation to Tennessee and completed an accredited PGY1 residency program.
Submit the following application materials for Oncology Residency to be received by January 1.
Number of Positions: One Residency starting date: July 3
Estimated stipend - approx. $60,593*
*info has not been verified